Human Bcl9-2 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF4967
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, N/A
Applications
Validated:
Western Blot
Cited:
ELISA Capture, Immunocytochemistry, Immunoprecipitation
Label
Unconjugated
Antibody Source
Polyclonal Sheep IgG
Product Specifications
Immunogen
E. coli-derived recombinant human Bcl9-2
Met38-Val206
Accession # Q86UU0
Met38-Val206
Accession # Q86UU0
Specificity
Detects endogenous human Bcl9-2 in Western blots.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Scientific Data Images for Human Bcl9-2 Antibody
Detection of Human Bcl9-2 by Western Blot.
Western blot shows lysates of A172 human glioblastoma cell line and MCF-7 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Human Bcl9-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4967) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Bcl9-2 at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Applications for Human Bcl9-2 Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: A172 human glioblastoma cell line and MCF-7 human breast cancer cell line
Sample: A172 human glioblastoma cell line and MCF-7 human breast cancer cell line
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Bcl9-2
Bcl9-2 (B-cell lymphoma 9-like protein; also Bcl9L and B9L) is a 200-220 kDa transcriptional regulator that belongs to the Bcl9 family of proteins. It is expressed in multiple tissues, particularly breast, and serves to recruit Pygopus to the Wnt-pathway beta-catenin-TCF complex in the nucleus. Bcl9-2 and Bcl9 are considered evolutionary duplicates of Legless that perform the same task with different regulation. Human Bcl9-2 is 1499 amino acids (aa) in length. It contains two Pro-rich regions (aa 280-493 and 891-1378). There are four potential alternate start sites at Met879, Met1000, Met708 and Met472. The last two start sites are accompanied by a deletion of aa 1241-1286, and a 62 aa substitution for the C-terminal 167 aa, respectively. Over aa 38-206, human Bcl9-2 is 94% aa identical to mouse Bcl9-2. Bcl9-2 has been identified as a phosphoprotein in several human cancer cell lines and mouse liver.
Long Name
B Cell Lymphoma/Leukemia 9-like Protein
Alternate Names
Bcl92, DLNB11
Gene Symbol
BCL9L
UniProt
Additional Bcl9-2 Products
Product Documents for Human Bcl9-2 Antibody
Product Specific Notices for Human Bcl9-2 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...